CASI Pharmaceuticals, Inc. (CASI)
USD 1.95
(-2.01%)
USD 1.95
(-2.01%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -21.53 Million USD | -265.58% |
| 2022 | -24.06 Million USD | 76.17% |
| 2021 | -32.74 Million USD | -97.61% |
| 2020 | -31.35 Million USD | 48.38% |
| 2019 | -37.43 Million USD | -26.69% |
| 2018 | -25.79 Million USD | -133.44% |
| 2017 | -10.63 Million USD | -13.6% |
| 2016 | -9.35 Million USD | -31.95% |
| 2015 | -7.05 Million USD | -9.71% |
| 2014 | -26.12 Million USD | -12.82% |
| 2013 | -5.72 Million USD | -27.64% |
| 2012 | -4.48 Million USD | 1.23% |
| 2011 | -4.52 Million USD | -215.67% |
| 2010 | -4.46 Million USD | 78.3% |
| 2009 | -6.62 Million USD | 64.66% |
| 2008 | -21.32 Million USD | 27.45% |
| 2007 | -21.28 Million USD | -579.34% |
| 2006 | -22.63 Million USD | 129.64% |
| 2005 | -15.83 Million USD | 7.98% |
| 2004 | -11.84 Million USD | -4.16% |
| 2003 | -18.76 Million USD | 60.46% |
| 2002 | -42.55 Million USD | 46.25% |
| 2001 | -65.43 Million USD | -72.35% |
| 2000 | -49.64 Million USD | -31.82% |
| 1999 | -37.58 Million USD | -128.49% |
| 1998 | -15 Million USD | -50.88% |
| 1997 | -8.8 Million USD | -39.02% |
| 1996 | -6.2 Million USD | -8.9% |
| 1995 | -7.53 Million USD | -52.12% |
| 1994 | -4.95 Million USD | 18.45% |
| 1993 | -6.07 Million USD | -352.99% |
| 1992 | -1.34 Million USD | -6600.0% |
| 1991 | -20 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -8.81 Million USD | -228.27% |
| 2024 Q2 | -12.18 Million USD | -47.02% |
| 2023 FY | - USD | -265.58% |
| 2023 Q4 | -1.96 Million USD | 63.61% |
| 2023 Q1 | -7.19 Million USD | -157.35% |
| 2023 Q3 | -5.41 Million USD | 34.96% |
| 2023 Q2 | -8.31 Million USD | -15.69% |
| 2022 Q3 | -6.92 Million USD | 9.09% |
| 2022 Q1 | -5.63 Million USD | 66.82% |
| 2022 FY | - USD | 76.17% |
| 2022 Q4 | 12.53 Million USD | 281.13% |
| 2022 Q2 | -7.61 Million USD | -35.12% |
| 2021 Q3 | -2.77 Million USD | 56.58% |
| 2021 Q4 | -16.98 Million USD | -511.38% |
| 2021 FY | - USD | -97.61% |
| 2021 Q1 | -5.86 Million USD | -8.17% |
| 2021 Q2 | -6.39 Million USD | -9.03% |
| 2020 FY | - USD | 48.38% |
| 2020 Q1 | -7.85 Million USD | 14.13% |
| 2020 Q2 | -5.5 Million USD | 29.92% |
| 2020 Q3 | 2.05 Million USD | 137.36% |
| 2020 Q4 | -5.42 Million USD | -363.73% |
| 2019 Q3 | -10.85 Million USD | -212.22% |
| 2019 Q4 | -9.15 Million USD | 15.73% |
| 2019 Q2 | -3.47 Million USD | 55.12% |
| 2019 Q1 | -7.74 Million USD | 8.48% |
| 2019 FY | - USD | -26.69% |
| 2018 Q4 | -8.46 Million USD | -2.01% |
| 2018 Q1 | -2.58 Million USD | 48.16% |
| 2018 Q2 | -5.43 Million USD | -110.16% |
| 2018 FY | - USD | -133.44% |
| 2018 Q3 | -8.29 Million USD | -52.71% |
| 2017 Q1 | -1.67 Million USD | 36.84% |
| 2017 Q4 | -4.98 Million USD | -219.34% |
| 2017 Q3 | -1.56 Million USD | 34.79% |
| 2017 FY | - USD | -13.6% |
| 2017 Q2 | -2.39 Million USD | -43.37% |
| 2016 Q4 | -2.64 Million USD | -58.23% |
| 2016 Q3 | -1.67 Million USD | 48.77% |
| 2016 Q2 | -3.26 Million USD | -84.96% |
| 2016 FY | - USD | -31.95% |
| 2016 Q1 | -1.76 Million USD | -4.64% |
| 2015 FY | - USD | -9.71% |
| 2015 Q3 | -1.59 Million USD | 21.75% |
| 2015 Q2 | -2.04 Million USD | -16.36% |
| 2015 Q1 | -1.75 Million USD | -11.46% |
| 2015 Q4 | -1.68 Million USD | -5.5% |
| 2014 Q2 | -1.6 Million USD | -11.0% |
| 2014 FY | - USD | -12.82% |
| 2014 Q4 | -1.57 Million USD | 14.1% |
| 2014 Q3 | -1.83 Million USD | -14.33% |
| 2014 Q1 | -1.44 Million USD | -10.77% |
| 2013 Q3 | -1.43 Million USD | 22.14% |
| 2013 Q4 | -1.3 Million USD | 9.34% |
| 2013 FY | - USD | -27.64% |
| 2013 Q1 | -1.13 Million USD | -218.62% |
| 2013 Q2 | -1.84 Million USD | -63.3% |
| 2012 Q1 | -1.65 Million USD | -264.0% |
| 2012 Q3 | -1.18 Million USD | 8.56% |
| 2012 FY | - USD | 1.23% |
| 2012 Q4 | -355.15 Thousand USD | 69.95% |
| 2012 Q2 | -1.29 Million USD | 21.84% |
| 2011 Q4 | 1 Million USD | 183.9% |
| 2011 Q3 | -1.2 Million USD | 27.23% |
| 2011 Q1 | -2.69 Million USD | -332.74% |
| 2011 Q2 | -1.65 Million USD | 38.7% |
| 2011 FY | - USD | -215.67% |
| 2010 Q3 | -1.96 Million USD | -259.29% |
| 2010 Q4 | 1.15 Million USD | 159.02% |
| 2010 FY | - USD | 78.3% |
| 2010 Q1 | -1.86 Million USD | -45.96% |
| 2010 Q2 | 1.23 Million USD | 166.0% |
| 2009 Q2 | -2.65 Million USD | 15.0% |
| 2009 Q3 | 439.34 Thousand USD | 116.53% |
| 2009 FY | - USD | 64.66% |
| 2009 Q4 | -1.27 Million USD | -390.93% |
| 2009 Q1 | -3.12 Million USD | -148.31% |
| 2008 FY | - USD | 27.45% |
| 2008 Q1 | -8.17 Million USD | -88.93% |
| 2008 Q2 | -5.22 Million USD | 36.05% |
| 2008 Q3 | -3.17 Million USD | 39.21% |
| 2008 Q4 | -1.25 Million USD | 60.34% |
| 2007 Q2 | -8.45 Million USD | -2.69% |
| 2007 FY | - USD | -579.34% |
| 2007 Q4 | -4.32 Million USD | -16.04% |
| 2007 Q3 | -3.72 Million USD | 55.9% |
| 2007 Q1 | -8.23 Million USD | -2.54% |
| 2006 FY | - USD | 129.64% |
| 2006 Q3 | -4.01 Million USD | 29.91% |
| 2006 Q4 | -8.02 Million USD | -99.72% |
| 2006 Q2 | -5.73 Million USD | -124.45% |
| 2006 Q1 | 23.44 Million USD | 945.91% |
| 2005 Q1 | -5.48 Million USD | 16.11% |
| 2005 Q4 | -2.77 Million USD | 42.67% |
| 2005 FY | - USD | 7.98% |
| 2005 Q3 | -4.83 Million USD | -2.44% |
| 2005 Q2 | -4.72 Million USD | 13.98% |
| 2004 Q1 | -4.8 Million USD | 20.84% |
| 2004 Q4 | -6.54 Million USD | -57.01% |
| 2004 FY | - USD | -4.16% |
| 2004 Q3 | -4.16 Million USD | 0.1% |
| 2004 Q2 | -4.16 Million USD | 13.18% |
| 2003 FY | - USD | 60.46% |
| 2003 Q4 | -6.06 Million USD | -40.12% |
| 2003 Q1 | -3.38 Million USD | 69.48% |
| 2003 Q3 | -4.28 Million USD | 13.41% |
| 2003 Q2 | -4.95 Million USD | -45.24% |
| 2002 Q3 | -11.31 Million USD | -3.61% |
| 2002 FY | - USD | 46.25% |
| 2002 Q1 | -14.22 Million USD | 40.22% |
| 2002 Q2 | -10.86 Million USD | 23.87% |
| 2002 Q4 | -6.15 Million USD | 0.64% |
| 2001 Q2 | -14.82 Million USD | -38.16% |
| 2001 Q4 | -23.8 Million USD | 38.23% |
| 2001 FY | - USD | -72.35% |
| 2001 Q1 | -10.62 Million USD | 22.87% |
| 2001 Q3 | -16.18 Million USD | -156.18% |
| 2000 Q3 | -11.71 Million USD | 9.55% |
| 2000 FY | - USD | -31.82% |
| 2000 Q1 | -10.79 Million USD | 27.89% |
| 2000 Q2 | -13.3 Million USD | -22.65% |
| 2000 Q4 | -13.81 Million USD | -14.41% |
| 1999 Q4 | -15.1 Million USD | -102.6% |
| 1999 FY | - USD | -128.49% |
| 1999 Q3 | -7.15 Million USD | 8.33% |
| 1999 Q2 | -8.09 Million USD | -9.09% |
| 1999 Q1 | -7.29 Million USD | -37.5% |
| 1998 Q1 | -3.4 Million USD | -25.81% |
| 1998 FY | - USD | -50.88% |
| 1998 Q4 | -5.1 Million USD | -12.0% |
| 1998 Q3 | -4.4 Million USD | -85.19% |
| 1998 Q2 | -2.1 Million USD | 30.77% |
| 1997 Q1 | -1.9 Million USD | 13.33% |
| 1997 Q4 | -2.5 Million USD | 0.0% |
| 1997 FY | - USD | -39.02% |
| 1997 Q3 | -2.4 Million USD | -24.0% |
| 1997 Q2 | -2.5 Million USD | 3.85% |
| 1996 Q2 | -500 Thousand USD | 61.11% |
| 1996 Q3 | -1.9 Million USD | -271.43% |
| 1996 Q4 | -3 Million USD | -15.38% |
| 1996 FY | - USD | -8.9% |
| 1996 Q1 | -1.8 Million USD | 28.85% |
| 1995 Q1 | -1.99 Million USD | 0.0% |
| 1995 FY | - USD | -52.12% |
| 1995 Q2 | -1.47 Million USD | 26.13% |
| 1995 Q3 | -1.54 Million USD | -4.76% |
| 1995 Q4 | -2.53 Million USD | -64.29% |
| 1994 FY | - USD | 18.45% |
| 1993 FY | - USD | -352.99% |
| 1992 FY | - USD | -6600.0% |
| 1991 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| NeuroSense Therapeutics Ltd. | -10.63 Million USD | -102.567% |
| Psyence Biomedical Ltd. | -2.75 Million USD | -682.787% |
| XOMA Corporation | -39.36 Million USD | 45.28% |
| Mesoblast Limited | -61.33 Million USD | 64.881% |
| Xeris Biopharma Holdings, Inc. | -23.73 Million USD | 9.252% |
| Aptorum Group Limited | -9.59 Million USD | -124.388% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | -90.605% |
| HilleVax, Inc. | -132.46 Million USD | 83.74% |
| Rocket Pharmaceuticals, Inc. | -236.62 Million USD | 90.897% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | 51.529% |
| Precision BioSciences, Inc. | -32.04 Million USD | 32.779% |
| Dyadic International, Inc. | -8.22 Million USD | -161.722% |
| Intensity Therapeutics, Inc. | -10.08 Million USD | -113.553% |
| IDEAYA Biosciences, Inc. | -130.42 Million USD | 83.485% |
| Eton Pharmaceuticals, Inc. | -291 Thousand USD | -7301.718% |
| VYNE Therapeutics Inc. | -29.25 Million USD | 26.383% |
| EyePoint Pharmaceuticals, Inc. | -69 Million USD | 68.785% |
| Adaptive Biotechnologies Corporation | -189.27 Million USD | 88.62% |
| Tenaya Therapeutics, Inc. | -122.5 Million USD | 82.418% |
| IGM Biosciences, Inc. | -253.35 Million USD | 91.499% |
| Opthea Limited | -200.01 Million USD | 89.232% |
| Milestone Pharmaceuticals Inc. | -56.84 Million USD | 62.109% |
| Abeona Therapeutics Inc. | -50.57 Million USD | 57.409% |
| Tonix Pharmaceuticals Holding Corp. | -114.08 Million USD | 81.121% |
| Ligand Pharmaceuticals Incorporated | 101.72 Million USD | 121.173% |
| NextCure, Inc. | -59.03 Million USD | 63.517% |
| Inhibikase Therapeutics, Inc. | -19.91 Million USD | -8.169% |
| Ovid Therapeutics Inc. | -58.71 Million USD | 63.315% |
| Arcturus Therapeutics Holdings Inc. | -24.16 Million USD | 10.871% |
| Syros Pharmaceuticals, Inc. | -157.19 Million USD | 86.298% |
| Senti Biosciences, Inc. | -61.33 Million USD | 64.884% |
| Apollomics, Inc. | -171.74 Million USD | 87.459% |
| PureTech Health plc | -11.62 Million USD | -85.25% |
| Oncternal Therapeutics, Inc. | 2.23 Million USD | 1063.714% |
| Barinthus Biotherapeutics plc | -74.81 Million USD | 71.21% |
| Kymera Therapeutics, Inc. | -143.2 Million USD | 84.959% |
| ChromaDex Corporation | -3.89 Million USD | -453.133% |
| Monopar Therapeutics Inc. | 429.03 Thousand USD | 5120.29% |
| Akebia Therapeutics, Inc. | -6.86 Million USD | -213.614% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 75.363% |
| Dermata Therapeutics, Inc. | 247.21 Thousand USD | 8812.624% |
| Gritstone bio, Inc. | -126.86 Million USD | 83.022% |
| Virpax Pharmaceuticals, Inc. | -2.24 Million USD | -857.408% |
| Fate Therapeutics, Inc. | -172.22 Million USD | 87.494% |
| BioXcel Therapeutics, Inc. | -165.42 Million USD | 86.979% |
| Fortress Biotech, Inc. | -133.64 Million USD | 83.883% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | 58.696% |
| Atossa Therapeutics, Inc. | -31.35 Million USD | 31.304% |
| Lyell Immunopharma, Inc. | -225.24 Million USD | 90.438% |
| Celcuity Inc. | -58.3 Million USD | 63.061% |
| ContextLogic Inc. | -324 Million USD | 93.352% |
| GH Research PLC | -41.15 Million USD | 47.661% |
| HOOKIPA Pharma Inc. | -77.34 Million USD | 72.151% |
| Cassava Sciences, Inc. | -95.68 Million USD | 77.49% |
| Cyclacel Pharmaceuticals, Inc. | -25.42 Million USD | 15.274% |
| ImmuCell Corporation | -2.5 Million USD | -760.157% |
| Amarin Corporation plc | -50.9 Million USD | 57.685% |
| TG Therapeutics, Inc. | 26.1 Million USD | 182.525% |
| X4 Pharmaceuticals, Inc. | -107.1 Million USD | 79.889% |
| Acelyrin, Inc. | -381.52 Million USD | 94.355% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -349.528% |
| Seer, Inc. | -97.88 Million USD | 77.996% |
| Novavax, Inc. | -487.39 Million USD | 95.581% |
| Phathom Pharmaceuticals, Inc. | -159.04 Million USD | 86.458% |
| Jazz Pharmaceuticals plc | 1.44 Billion USD | 101.486% |
| AnaptysBio, Inc. | -143.16 Million USD | 84.955% |
| Aptevo Therapeutics Inc. | -28.31 Million USD | 23.92% |
| PMV Pharmaceuticals, Inc. | -78.87 Million USD | 72.692% |
| AbCellera Biologics Inc. | -192.15 Million USD | 88.791% |
| CorMedix Inc. | -48.88 Million USD | 55.941% |
| Cartesian Therapeutics, Inc. | -235.06 Million USD | 90.837% |
| Marker Therapeutics, Inc. | -11.79 Million USD | -82.654% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 100.463% |
| Aptose Biosciences Inc. | -52.26 Million USD | 58.791% |
| ZyVersa Therapeutics, Inc. | -107.74 Million USD | 80.009% |
| Soligenix, Inc. | -7.85 Million USD | -174.283% |
| Century Therapeutics, Inc. | -121.2 Million USD | 82.23% |
| Arrowhead Pharmaceuticals, Inc. | -175.67 Million USD | 87.739% |
| TransCode Therapeutics, Inc. | -17.97 Million USD | -19.838% |
| Kura Oncology, Inc. | -164.95 Million USD | 86.942% |
| RAPT Therapeutics, Inc. | -125.84 Million USD | 82.885% |
| Ardelyx, Inc. | -55.35 Million USD | 61.089% |
| Ainos, Inc. | -8.77 Million USD | -145.512% |
| TScan Therapeutics, Inc. | -80.09 Million USD | 73.109% |
| Ocean Biomedical, Inc. | -957.73 Thousand USD | -2148.943% |
| Prothena Corporation plc | -190.1 Million USD | 88.67% |
| CytomX Therapeutics, Inc. | -4.3 Million USD | -399.861% |
| Autolus Therapeutics plc | -156.77 Million USD | 86.261% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 74.557% |
| Adaptimmune Therapeutics plc | -128.19 Million USD | 83.199% |
| Eterna Therapeutics Inc. | -19.93 Million USD | -8.052% |
| Celularity Inc. | -183.94 Million USD | 88.291% |
| Rallybio Corporation | -72.37 Million USD | 70.239% |
| GRI Bio, Inc. | -10.89 Million USD | -97.642% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | -376.979% |
| Omeros Corporation | -163.61 Million USD | 86.835% |
| INmune Bio, Inc. | - USD | Infinity% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 79.248% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | 43.516% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | -40.494% |
| Entero Therapeutics, Inc. | -15.74 Million USD | -36.814% |
| Humacyte, Inc. | -96.45 Million USD | 77.67% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 91.903% |
| Coherus BioSciences, Inc. | -193.93 Million USD | 88.894% |
| Immunocore Holdings plc | -59.64 Million USD | 63.89% |
| Cocrystal Pharma, Inc. | -19.37 Million USD | -11.186% |
| Verastem, Inc. | -83.16 Million USD | 74.101% |
| Pliant Therapeutics, Inc. | -158.22 Million USD | 86.387% |
| Histogen Inc. | -10.5 Million USD | -105.075% |
| Surrozen, Inc. | -41.13 Million USD | 47.633% |
| Blueprint Medicines Corporation | -474.61 Million USD | 95.462% |
| Organovo Holdings, Inc. | -14.8 Million USD | -45.475% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | 671724.571% |
| IO Biotech, Inc. | -91.22 Million USD | 76.39% |
| MEI Pharma, Inc. | 26.38 Million USD | 181.649% |
| GT Biopharma, Inc. | 5.97 Million USD | 460.244% |
| Centessa Pharmaceuticals plc | -166.06 Million USD | 87.03% |
| Hepion Pharmaceuticals, Inc. | -49.25 Million USD | 56.274% |
| Cabaletta Bio, Inc. | -73.23 Million USD | 70.589% |
| Summit Therapeutics Inc. | 1 Million USD | 2251.748% |
| Alaunos Therapeutics, Inc. | -30.9 Million USD | 30.304% |
| Marinus Pharmaceuticals, Inc. | -125.49 Million USD | 82.837% |
| BioRestorative Therapies, Inc. | -15.05 Million USD | -43.068% |
| Turnstone Biologics Corp. | -56.23 Million USD | 61.698% |
| Pulmatrix, Inc. | -12.64 Million USD | -70.323% |
| Synaptogenix, Inc. | -8.3 Million USD | -159.272% |
| Tiziana Life Sciences Ltd | -15.33 Million USD | -40.42% |
| Aurinia Pharmaceuticals Inc. | -63.04 Million USD | 65.837% |
| Vigil Neuroscience, Inc. | -88.46 Million USD | 75.653% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 95.746% |
| Cytokinetics, Incorporated | -456.68 Million USD | 95.284% |
| Exelixis, Inc. | 196.6 Million USD | 110.956% |
| Nurix Therapeutics, Inc. | -141.4 Million USD | 84.768% |
| Apellis Pharmaceuticals, Inc. | -495.21 Million USD | 95.651% |
| Evogene Ltd. | -23.2 Million USD | 7.175% |
| Replimune Group, Inc. | -230.19 Million USD | 90.643% |
| PDS Biotechnology Corporation | -40.08 Million USD | 46.267% |
| Hoth Therapeutics, Inc. | -153.14 Thousand USD | -13964.081% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | 66.855% |
| ESSA Pharma Inc. | -26.45 Million USD | 18.583% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | -438.482% |
| BioLineRx Ltd. | -57.06 Million USD | 62.253% |
| Avid Bioservices, Inc. | -11.48 Million USD | -87.606% |
| Insmed Incorporated | -654.73 Million USD | 96.71% |
| VistaGen Therapeutics, Inc. | -32.45 Million USD | 33.63% |
| Zentalis Pharmaceuticals, Inc. | -275.5 Million USD | 92.182% |
| Sagimet Biosciences Inc. | -30.74 Million USD | 29.932% |
| MediWound Ltd. | -4.89 Million USD | -340.2% |
| MiMedx Group, Inc. | 40.51 Million USD | 153.16% |
| OmniAb, Inc. | -49.73 Million USD | 56.689% |
| Alector, Inc. | -142.89 Million USD | 84.926% |
| Seres Therapeutics, Inc. | -85.43 Million USD | 74.789% |
| PTC Therapeutics, Inc. | -330.34 Million USD | 93.48% |
| Mereo BioPharma Group plc | -26.05 Million USD | 17.336% |
| Zai Lab Limited | -366.57 Million USD | 94.124% |
| Revance Therapeutics, Inc. | -290.63 Million USD | 92.589% |
| Syndax Pharmaceuticals, Inc. | -229.94 Million USD | 90.633% |
| Aura Biosciences, Inc. | -83.69 Million USD | 74.265% |
| Immunic, Inc. | -99.11 Million USD | 78.268% |
| Dyne Therapeutics, Inc. | -233.47 Million USD | 90.775% |
| Tarsus Pharmaceuticals, Inc. | -131.67 Million USD | 83.642% |
| Veracyte, Inc. | -49.4 Million USD | 56.407% |
| InMed Pharmaceuticals Inc. | -7.06 Million USD | -204.915% |
| FibroGen, Inc. | -261.4 Million USD | 91.76% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | -93.331% |
| Allakos Inc. | -189.91 Million USD | 88.659% |
| scPharmaceuticals Inc. | -46.06 Million USD | 53.238% |
| Fulcrum Therapeutics, Inc. | -108.49 Million USD | 80.147% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 119.884% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | -207.642% |
| NLS Pharmaceutics AG | -11.79 Million USD | -82.601% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.71 Million USD | -15.078% |
| Amylyx Pharmaceuticals, Inc. | 39.89 Million USD | 153.996% |
| Precigen, Inc. | -89.22 Million USD | 75.86% |
| Fortrea Holdings Inc. | 167.3 Million USD | 112.874% |
| KalVista Pharmaceuticals, Inc. | -134.28 Million USD | 83.96% |
| Incyte Corporation | 919.42 Million USD | 102.343% |
| Alzamend Neuro, Inc. | -9.88 Million USD | -117.854% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 81.692% |
| XBiotech Inc. | -35.76 Million USD | 39.778% |
| Aligos Therapeutics, Inc. | -83.81 Million USD | 74.302% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | 66.855% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | 10.671% |
| CRISPR Therapeutics AG | -202.7 Million USD | 89.374% |
| Akero Therapeutics, Inc. | -148.63 Million USD | 85.508% |
| Eliem Therapeutics, Inc. | -13.65 Million USD | -57.76% |
| Lyra Therapeutics, Inc. | -65.25 Million USD | 66.99% |
| Foghorn Therapeutics Inc. | -104.45 Million USD | 79.38% |
| Agenus Inc. | -145.92 Million USD | 85.24% |
| Kiora Pharmaceuticals, Inc. | -12.35 Million USD | -74.405% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | 16.099% |
| Theravance Biopharma, Inc. | -40.86 Million USD | 47.295% |
| Ultragenyx Pharmaceutical Inc. | -516.45 Million USD | 95.829% |
| Metagenomi, Inc. Common Stock | -56.02 Million USD | 61.552% |
| Lexaria Bioscience Corp. | -6.38 Million USD | -237.146% |
| BioCryst Pharmaceuticals, Inc. | -116.33 Million USD | 81.485% |
| UroGen Pharma Ltd. | -63.83 Million USD | 66.256% |
| Gain Therapeutics, Inc. | -22.16 Million USD | 2.844% |
| Sutro Biopharma, Inc. | -67.91 Million USD | 68.285% |
| Creative Medical Technology Holdings, Inc. | -5.52 Million USD | -289.807% |
| Lisata Therapeutics, Inc. | -25.51 Million USD | 15.596% |
| Chemomab Therapeutics Ltd. | -25.39 Million USD | 15.174% |
| Stoke Therapeutics, Inc. | -112.3 Million USD | 80.821% |
| Chimerix, Inc. | -92.97 Million USD | 76.833% |
| Reneo Pharmaceuticals, Inc. | -82.23 Million USD | 73.807% |
| Outlook Therapeutics, Inc. | -57.37 Million USD | 62.46% |
| 60 Degrees Pharmaceuticals, Inc. | -1.42 Million USD | -1409.872% |
| Pluri Inc. | -20.22 Million USD | -6.497% |
| Cue Biopharma, Inc. | -46.05 Million USD | 53.229% |
| MeiraGTx Holdings plc | -57.05 Million USD | 62.247% |
| Aprea Therapeutics, Inc. | -14.27 Million USD | -50.836% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.33 Million USD | -158.323% |
| Cidara Therapeutics, Inc. | -24.36 Million USD | 11.599% |
| ProMIS Neurosciences, Inc. | -17.8 Million USD | -20.94% |
| CalciMedica, Inc. | -34.18 Million USD | 37.0% |
| Scholar Rock Holding Corporation | -168.45 Million USD | 87.213% |
| Sana Biotechnology, Inc. | -252.39 Million USD | 91.466% |
| Elicio Therapeutics, Inc. | -32.96 Million USD | 34.663% |
| NLS Pharmaceutics AG | -11.79 Million USD | -82.601% |
| Adlai Nortye Ltd. American Depositary Shares | -101.21 Million USD | 78.72% |
| Nutriband Inc. | -5.12 Million USD | -320.538% |
| Protara Therapeutics, Inc. | -43.27 Million USD | 50.224% |
| Vor Biopharma Inc. | -114.37 Million USD | 81.167% |
| Roivant Sciences Ltd. | -996.51 Million USD | 97.839% |
| ProKidney Corp. | -147.66 Million USD | 85.414% |
| Applied Therapeutics, Inc. | -64.53 Million USD | 66.624% |
| Daré Bioscience, Inc. | -30.7 Million USD | 29.844% |
| BridgeBio Pharma, Inc. | -565.46 Million USD | 96.191% |
| Titan Pharmaceuticals, Inc. | -7.16 Million USD | -200.614% |
| Bicycle Therapeutics plc | -183.4 Million USD | 88.256% |
| Tango Therapeutics, Inc. | -111.75 Million USD | 80.727% |
| Galectin Therapeutics Inc. | -202 Thousand USD | -10562.871% |
| Revolution Medicines, Inc. Warrant | -430.58 Million USD | 94.998% |
| Atai Life Sciences N.V. | -36.31 Million USD | 40.682% |
| Renovaro Biosciences Inc. | -79.51 Million USD | 72.913% |
| Aerovate Therapeutics, Inc. | -81.31 Million USD | 73.511% |
| MediciNova, Inc. | -9.87 Million USD | -118.007% |
| Praxis Precision Medicines, Inc. | -125.94 Million USD | 82.898% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | -1307.593% |
| GeoVax Labs, Inc. | -26.66 Million USD | 19.235% |
| Protagonist Therapeutics, Inc. | -90.34 Million USD | 76.158% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 90.427% |
| Biomea Fusion, Inc. | -124.62 Million USD | 82.716% |
| RenovoRx, Inc. | -11.39 Million USD | -89.104% |
| Erasca, Inc. | -121.31 Million USD | 82.245% |
| Cullinan Oncology, Inc. | -190.33 Million USD | 88.684% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | 28.263% |
| 4D Molecular Therapeutics, Inc. | -107.11 Million USD | 79.892% |
| Kiniksa Pharmaceuticals, Ltd. | -22.85 Million USD | 5.758% |
| bluebird bio, Inc. | -167.16 Million USD | 87.115% |
| Ventyx Biosciences, Inc. | -207.83 Million USD | 89.637% |
| Pieris Pharmaceuticals, Inc. | -22.76 Million USD | 5.373% |
| Imunon, Inc. | -19.87 Million USD | -8.354% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 106.942% |
| BioAtla, Inc. | -122.24 Million USD | 82.38% |
| Allogene Therapeutics, Inc. | -300.29 Million USD | 92.827% |
| Larimar Therapeutics, Inc. | -41.44 Million USD | 48.032% |
| DBV Technologies S.A. | -85.98 Million USD | 74.949% |
| Fortress Biotech, Inc. | -133.64 Million USD | 83.883% |
| Avidity Biosciences, Inc. | -233.49 Million USD | 90.775% |
| Kezar Life Sciences, Inc. | -99.25 Million USD | 78.299% |
| aTyr Pharma, Inc. | -52.17 Million USD | 58.72% |
| Viridian Therapeutics, Inc. | -234.56 Million USD | 90.817% |
| EyeGate Pharmaceuticals, Inc. | -8.04 Million USD | -167.821% |
| Galecto, Inc. | -37.51 Million USD | 42.592% |
| Akari Therapeutics, Plc | -16.8 Million USD | -28.193% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | 11514.051% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 104.766% |
| Lexicon Pharmaceuticals, Inc. | -163.46 Million USD | 86.823% |
| Entera Bio Ltd. | -8.8 Million USD | -144.65% |
| Travere Therapeutics, Inc. | -326.24 Million USD | 93.398% |
| Sensei Biotherapeutics, Inc. | -33.38 Million USD | 35.485% |
| Xencor, Inc. | -125.87 Million USD | 82.888% |
| Orchestra BioMed Holdings, Inc. | -51.21 Million USD | 57.947% |
| Spruce Biosciences, Inc. | -47.36 Million USD | 54.526% |
| Coeptis Therapeutics Holdings, Inc. | -20.15 Million USD | -6.853% |
| Vanda Pharmaceuticals Inc. | -10.94 Million USD | -96.847% |
| Lexaria Bioscience Corp. | -6.38 Million USD | -237.146% |
| Portage Biotech Inc. | -18.19 Million USD | -18.353% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | -1307.593% |
| Olema Pharmaceuticals, Inc. | -104.58 Million USD | 79.405% |
| OncoCyte Corporation | -23.12 Million USD | 6.85% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | -88.001% |
| Purple Biotech Ltd. | -22.22 Million USD | 3.087% |
| CollPlant Biotechnologies Ltd. | -6.41 Million USD | -236.022% |
| Onconetix, Inc. | -36.7 Million USD | 41.321% |
| MacroGenics, Inc. | 2.01 Million USD | 1167.873% |
| Tharimmune, Inc. | -9.3 Million USD | -131.538% |
| Genprex, Inc. | -31.06 Million USD | 30.655% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 74.354% |
| Neumora Therapeutics, Inc. Common Stock | -187.52 Million USD | 88.514% |
| Ocuphire Pharma, Inc. | -9.96 Million USD | -116.081% |
| Prime Medicine, Inc. | -193.75 Million USD | 88.884% |
| Aditxt, Inc. | -25.45 Million USD | 15.394% |
| XTL Biopharmaceuticals Ltd. | -764 Thousand USD | -2719.241% |
| Virios Therapeutics, Inc. | 150.9 Thousand USD | 14373.313% |
| OKYO Pharma Limited | -15.74 Thousand USD | -136691.425% |
| Savara Inc. | -59.13 Million USD | 63.575% |
| Curis, Inc. | -45.13 Million USD | 52.283% |
| Carmell Therapeutics Corporation | -15.19 Million USD | -41.787% |
| Adagene Inc. | -14.95 Million USD | -44.066% |
| Achieve Life Sciences, Inc. | -26.73 Million USD | 19.432% |
| BeiGene, Ltd. | -1.12 Billion USD | 98.085% |
| Inhibrx Biosciences, Inc. | -206.69 Million USD | 89.579% |
| GlycoMimetics, Inc. | -39.12 Million USD | 44.944% |
| Maravai LifeSciences Holdings, Inc. | 712.4 Million USD | 103.023% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | -378.777% |
| SciSparc Ltd. | -5.28 Million USD | -307.781% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | -378.777% |
| Vincerx Pharma, Inc. | -42.6 Million USD | 49.45% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | -22523.099% |
| Minerva Neurosciences, Inc. | -21.69 Million USD | 0.703% |
| Fresh Tracks Therapeutics, Inc. | -5.64 Million USD | -281.356% |
| Arcutis Biotherapeutics, Inc. | -227.43 Million USD | 90.53% |
| Acrivon Therapeutics, Inc. Common Stock | -59.85 Million USD | 64.013% |
| Alnylam Pharmaceuticals, Inc. | -258.24 Million USD | 91.659% |
| ADMA Biologics, Inc. | 5.12 Million USD | 520.684% |
| Rigel Pharmaceuticals, Inc. | -16.98 Million USD | -26.842% |
| Clene Inc. | -43.24 Million USD | 50.188% |
| Celldex Therapeutics, Inc. | -139.03 Million USD | 84.508% |
| Cogent Biosciences, Inc. | -205.86 Million USD | 89.537% |
| Boundless Bio, Inc. Common Stock | -48.47 Million USD | 55.569% |
| Recursion Pharmaceuticals, Inc. | -299.56 Million USD | 92.81% |
| Adicet Bio, Inc. | -136.53 Million USD | 84.225% |
| Contineum Therapeutics, Inc. Class A Common Stock | 23.57 Million USD | 191.371% |
| Absci Corporation | -95.45 Million USD | 77.436% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -194.647% |
| Quantum-Si incorporated | -91.8 Million USD | 76.538% |
| Acurx Pharmaceuticals, Inc. | - USD | Infinity% |
| Voyager Therapeutics, Inc. | 126.45 Million USD | 117.033% |
| Surrozen, Inc. | -41.13 Million USD | 47.633% |
| Generation Bio Co. | -133.3 Million USD | 83.842% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 74.059% |
| Caribou Biosciences, Inc. | -112.53 Million USD | 80.86% |
| Black Diamond Therapeutics, Inc. | -86.02 Million USD | 74.961% |
| Janux Therapeutics, Inc. | -71.02 Million USD | 69.674% |
| Invivyd, Inc. | -196.61 Million USD | 89.045% |
| Cingulate Inc. | -22.95 Million USD | 6.156% |
| Relay Therapeutics, Inc. | -374.15 Million USD | 94.243% |
| Quoin Pharmaceuticals, Ltd. | -9.27 Million USD | -132.231% |
| Tenax Therapeutics, Inc. | -8.22 Million USD | -161.829% |
| Spero Therapeutics, Inc. | 27.15 Million USD | 179.322% |
| Jaguar Health, Inc. | -33.13 Million USD | 34.988% |
| Artelo Biosciences, Inc. | -10.28 Million USD | -109.421% |
| 2seventy bio, Inc. | -206.41 Million USD | 89.565% |
| Clearside Biomedical, Inc. | -23.05 Million USD | 6.588% |
| Terns Pharmaceuticals, Inc. | -102.26 Million USD | 78.938% |
| ACADIA Pharmaceuticals Inc. | -67.82 Million USD | 68.244% |
| Capricor Therapeutics, Inc. | -23 Million USD | 6.389% |
| Citius Pharmaceuticals, Inc. | -36.72 Million USD | 41.358% |
| Relmada Therapeutics, Inc. | 4.91 Million USD | 538.653% |
| Kronos Bio, Inc. | -121.83 Million USD | 82.32% |
| Innoviva, Inc. | 248.96 Million USD | 108.652% |
| Bolt Biotherapeutics, Inc. | -74.34 Million USD | 71.027% |
| Entrada Therapeutics, Inc. | -321 Thousand USD | -6609.969% |
| ALX Oncology Holdings Inc. | -158.4 Million USD | 86.402% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 96.852% |
| Evaxion Biotech A/S | -21.4 Million USD | -0.635% |
| Ocular Therapeutix, Inc. | -66.41 Million USD | 67.569% |
| Verve Therapeutics, Inc. | -217.66 Million USD | 90.105% |
| Tyra Biosciences, Inc. | -79.59 Million USD | 72.938% |
| Galmed Pharmaceuticals Ltd. | -7.46 Million USD | -188.688% |
| Unity Biotechnology, Inc. | -37.28 Million USD | 42.228% |
| Connect Biopharma Holdings Limited | -58.37 Million USD | 63.1% |
| Clearmind Medicine Inc. | -8.71 Million USD | -147.272% |
| AlloVir, Inc. | -190.14 Million USD | 88.672% |
| ORIC Pharmaceuticals, Inc. | -109.74 Million USD | 80.374% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | 124.811% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | -782.235% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 78.638% |
| Keros Therapeutics, Inc. | -152.17 Million USD | 85.846% |
| SELLAS Life Sciences Group, Inc. | 529 Thousand USD | 4171.645% |
| Crinetics Pharmaceuticals, Inc. | -221.51 Million USD | 90.276% |
| ImmunityBio, Inc. | -436.18 Million USD | 95.062% |
| Korro Bio, Inc. | -80.9 Million USD | 73.377% |
| C4 Therapeutics, Inc. | -122.1 Million USD | 82.36% |
| Kineta, Inc. | -15.71 Million USD | -37.069% |
| Lantern Pharma Inc. | -15.78 Million USD | -36.438% |
| BioVie Inc. | -31.95 Million USD | 32.586% |
| Codexis, Inc. | -49.28 Million USD | 56.295% |
| Celularity Inc. | -183.94 Million USD | 88.291% |
| Eledon Pharmaceuticals, Inc. | - USD | Infinity% |
| Virax Biolabs Group Limited | -6.6 Million USD | -225.897% |
| Kodiak Sciences Inc. | -259.02 Million USD | 91.685% |
| Cibus, Inc. | -314.58 Million USD | 93.153% |
| Annexon, Inc. | -141.57 Million USD | 84.786% |
| Assembly Biosciences, Inc. | -64.19 Million USD | 66.448% |
| Moderna, Inc. | -3.28 Billion USD | 99.344% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 90.636% |
| Adverum Biotechnologies, Inc. | -112.59 Million USD | 80.871% |
| Avalo Therapeutics, Inc. | -27.95 Million USD | 22.951% |
| Immix Biopharma, Inc. | -16.13 Million USD | -33.487% |
| Eyenovia, Inc. | -24.1 Million USD | 10.649% |
| Puma Biotechnology, Inc. | 44.78 Million USD | 148.095% |
| Monte Rosa Therapeutics, Inc. | -137.08 Million USD | 84.288% |
| Wave Life Sciences Ltd. | -58.79 Million USD | 63.363% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | -6547.84% |
| Xilio Therapeutics, Inc. | -73.8 Million USD | 70.816% |
| Alkermes plc | 495.04 Million USD | 104.351% |
| Arcellx, Inc. | -64.14 Million USD | 66.421% |
| Moolec Science SA | -52.07 Million USD | 58.639% |
| Cardiff Oncology, Inc. | -45.01 Million USD | 52.15% |
| LAVA Therapeutics N.V. | -40.41 Million USD | 46.708% |
| Enanta Pharmaceuticals, Inc. | -123.47 Million USD | 82.556% |
| Regulus Therapeutics Inc. | -30.88 Million USD | 30.254% |
| Atea Pharmaceuticals, Inc. | -119.59 Million USD | 81.99% |
| Compass Therapeutics, Inc. | -48.47 Million USD | 55.565% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | -131.0% |
| Humacyte, Inc. | -96.45 Million USD | 77.67% |
| Acumen Pharmaceuticals, Inc. | -51.6 Million USD | 58.263% |
| Geron Corporation | -174.78 Million USD | 87.677% |
| Verrica Pharmaceuticals Inc. | -62.19 Million USD | 65.37% |
| Avenue Therapeutics, Inc. | 4.05 Million USD | 631.565% |
| Royalty Pharma plc | 1.88 Billion USD | 101.141% |
| TFF Pharmaceuticals, Inc. | -20.74 Million USD | -3.849% |
| Notable Labs, Ltd. | -14.4 Million USD | -49.576% |
| Mersana Therapeutics, Inc. | -166.08 Million USD | 87.031% |
| Structure Therapeutics Inc. | -102.45 Million USD | 78.978% |
| IN8bio, Inc. | -28.5 Million USD | 24.435% |
| 89bio, Inc. | -134.46 Million USD | 83.981% |
| DiaMedica Therapeutics Inc. | -19.3 Million USD | -11.555% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 78.886% |
| Acasti Pharma Inc. | -11.3 Million USD | -90.594% |
| Genelux Corporation | -24.16 Million USD | 10.867% |
| Trevi Therapeutics, Inc. | -33.8 Million USD | 36.275% |
| Liquidia Corporation | -70.05 Million USD | 69.252% |
| Mustang Bio, Inc. | -48.06 Million USD | 55.186% |
| Immunovant, Inc. | -269.97 Million USD | 92.022% |
| Vericel Corporation | 2.86 Million USD | 852.06% |
| Quantum-Si incorporated | -91.8 Million USD | 76.538% |
| Arbutus Biopharma Corporation | -70.98 Million USD | 69.657% |
| XOMA Corporation | -39.36 Million USD | 45.28% |
| ARS Pharmaceuticals, Inc. | -67.44 Million USD | 68.065% |
| MiNK Therapeutics, Inc. | -22.25 Million USD | 3.21% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | -40.494% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | 37.759% |
| Vaxcyte, Inc. | -464.88 Million USD | 95.367% |
| Xenon Pharmaceuticals Inc. | -210.51 Million USD | 89.768% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -194.647% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | -35.636% |
| Tempest Therapeutics, Inc. | -28.77 Million USD | 25.149% |
| Sol-Gel Technologies Ltd. | -28.96 Million USD | 25.633% |
| Rhythm Pharmaceuticals, Inc. | -168.46 Million USD | 87.214% |
| Soleno Therapeutics, Inc. | -37.03 Million USD | 41.834% |
| Enlivex Therapeutics Ltd. | -28.21 Million USD | 23.672% |
| PepGen Inc. | -83.58 Million USD | 74.23% |
| Moleculin Biotech, Inc. | -29.5 Million USD | 26.996% |
| United Therapeutics Corporation | 1.38 Billion USD | 101.553% |
| Solid Biosciences Inc. | -93.43 Million USD | 76.947% |
| BriaCell Therapeutics Corp. | -4.77 Million USD | -351.387% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | -6547.84% |
| Immuneering Corporation | -58.06 Million USD | 62.903% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | 671724.571% |
| Silo Pharma, Inc. | -3.62 Million USD | -493.98% |
| Telomir Pharmaceuticals, Inc. Common Stock | -6.11 Million USD | -252.143% |
| Belite Bio, Inc | -31.52 Million USD | 31.685% |
| Pharming Group N.V. | 9.87 Million USD | 318.072% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | 10.671% |
| Bionomics Limited | -9.83 Million USD | -118.959% |
| Pyxis Oncology, Inc. | -78.49 Million USD | 72.559% |
| uniQure N.V. | -253.1 Million USD | 91.49% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | -6.846% |
| GeoVax Labs, Inc. | -26.66 Million USD | 19.235% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 83.368% |
| Altimmune, Inc. | -87.93 Million USD | 75.506% |
| Anebulo Pharmaceuticals, Inc. | -8.05 Million USD | -167.549% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | 37.759% |
| Peak Bio, Inc. | -1356.23 USD | -1588052.452% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | -93.331% |
| FibroBiologics, Inc. Common Stock | -15.9 Million USD | -35.457% |
| Benitec Biopharma Inc. | -22.49 Million USD | 4.229% |
| Zura Bio Limited | -60.56 Million USD | 64.435% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 76.608% |
| Salarius Pharmaceuticals, Inc. | -12.88 Thousand USD | -167064.795% |
| Compugen Ltd. | -12.51 Million USD | -72.092% |
| Elevai Labs, Inc. Common Stock | -4.27 Million USD | -404.386% |
| argenx SE | -216.02 Million USD | 90.029% |
| Zevra Therapeutics, Inc. | -48.59 Million USD | 55.679% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 5.931% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 91.111% |
| NKGen Biotech, Inc. Common Stock | -28.54 Million USD | 24.538% |
| Madrigal Pharmaceuticals, Inc. | -379.96 Million USD | 94.331% |
| PolyPid Ltd. | -20.26 Million USD | -6.297% |
| Aileron Therapeutics, Inc. | -15.61 Million USD | -37.956% |
| Plus Therapeutics, Inc. | -12.69 Million USD | -69.692% |
| Forte Biosciences, Inc. | -32.47 Million USD | 33.679% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | 55.289% |
| Instil Bio, Inc. | -146.12 Million USD | 85.26% |
| Elevation Oncology, Inc. | -41.46 Million USD | 48.057% |
| Immunome, Inc. | -28.27 Million USD | 23.812% |
| Verona Pharma plc | -52.46 Million USD | 58.948% |
| Enveric Biosciences, Inc. | -17.13 Million USD | -25.665% |
| enGene Holdings Inc. Warrants | -94.77 Million USD | 77.273% |
| Shattuck Labs, Inc. | -87.61 Million USD | 75.416% |
| LENZ Therapeutics, Inc. | -122.24 Million USD | 82.38% |
| Design Therapeutics, Inc. | -66.32 Million USD | 67.525% |
| Leap Therapeutics, Inc. | -80.98 Million USD | 73.404% |
| Seelos Therapeutics, Inc. | -37.75 Million USD | 42.943% |
| Achilles Therapeutics plc | -70.44 Million USD | 69.423% |
| Fractyl Health, Inc. Common Stock | -50.55 Million USD | 57.391% |
| Rani Therapeutics Holdings, Inc. | -65.27 Million USD | 67.004% |
| MoonLake Immunotherapeutics | -54.1 Million USD | 60.194% |
| Beam Therapeutics Inc. | -156.47 Million USD | 86.235% |
| Moolec Science SA | -52.07 Million USD | 58.639% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | 62.048% |
| AEON Biopharma, Inc. | -48.36 Million USD | 55.462% |
| Aadi Bioscience, Inc. | -65.36 Million USD | 67.048% |
| Enliven Therapeutics, Inc. | -81.93 Million USD | 73.711% |
| Iovance Biotherapeutics, Inc. | -427.43 Million USD | 94.961% |
| Taysha Gene Therapies, Inc. | -105.19 Million USD | 79.525% |
| Inovio Pharmaceuticals, Inc. | -130.39 Million USD | 83.481% |
| Athira Pharma, Inc. | -116.7 Million USD | 81.544% |
| HCW Biologics Inc. | -23.57 Million USD | 8.64% |
| XOMA Corporation | -39.36 Million USD | 45.28% |
| NeurAxis, Inc. | -6.66 Million USD | -223.19% |
| Lumos Pharma, Inc. | -36.57 Million USD | 41.102% |
| enGene Holdings Inc. Common Stock | -94.77 Million USD | 77.273% |
| 180 Life Sciences Corp. | -22.13 Million USD | 2.688% |
| Nektar Therapeutics | -243.1 Million USD | 91.14% |
| NKGen Biotech, Inc. Warrants | -28.54 Million USD | 24.538% |
| Opiant Pharmaceuticals, Inc. | 5.82 Million USD | 469.499% |
| Arvinas, Inc. | -394.8 Million USD | 94.544% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | -782.235% |
| Palisade Bio, Inc. | -12.28 Million USD | -75.385% |
| Nutriband Inc. | -5.12 Million USD | -320.538% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | 11514.051% |
| CG Oncology, Inc. Common stock | -55.43 Million USD | 61.143% |
| Tourmaline Bio, Inc. | -45.37 Million USD | 52.532% |
| Merus N.V. | -149.2 Million USD | 85.564% |
| Omega Therapeutics, Inc. | -93.49 Million USD | 76.961% |
| Neurogene Inc. | -52.28 Million USD | 58.805% |
| Mirum Pharmaceuticals, Inc. | -136.49 Million USD | 84.219% |
| Kintara Therapeutics, Inc. | -8.39 Million USD | -156.539% |
| CervoMed Inc. | -2.17 Million USD | -891.724% |
| CARGO Therapeutics, Inc. Common Stock | -93.01 Million USD | 76.844% |
| Sesen Bio, Inc. | -50.84 Million USD | 57.634% |
| Quince Therapeutics, Inc. | -31.26 Million USD | 31.097% |
| Rezolute, Inc. | -68.42 Million USD | 68.521% |
| Clene Inc. | -43.24 Million USD | 50.188% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | -39.662% |
| BeyondSpring Inc. | -21.54 Million USD | 0.005% |
| Synlogic, Inc. | -55.16 Million USD | 60.952% |
| Allarity Therapeutics, Inc. | -12.08 Million USD | -78.259% |
| Phio Pharmaceuticals Corp. | -10.64 Million USD | -102.396% |
| Peak Bio, Inc. | -1356.23 USD | -1588052.452% |
| Werewolf Therapeutics, Inc. | -32.46 Million USD | 33.655% |
| Krystal Biotech, Inc. | 17.9 Million USD | 220.303% |
| Karyopharm Therapeutics Inc. | -118.42 Million USD | 81.812% |
| SpringWorks Therapeutics, Inc. | -341.34 Million USD | 93.69% |
| Lipella Pharmaceuticals Inc. | -4.6 Million USD | -367.585% |
| MannKind Corporation | 15.12 Million USD | 242.369% |
| Ikena Oncology, Inc. | -74.39 Million USD | 71.049% |
| Cyclerion Therapeutics, Inc. | -12.59 Million USD | -71.039% |
| Gyre Therapeutics, Inc. | 20.32 Million USD | 205.963% |
| Gossamer Bio, Inc. | -172.15 Million USD | 87.488% |
| CohBar, Inc. | -12.06 Million USD | -78.513% |
| Cognition Therapeutics, Inc. | -25.5 Million USD | 15.563% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | 28.263% |
| Legend Biotech Corporation | -477.87 Million USD | 95.493% |
| Mural Oncology plc | -192.72 Million USD | 88.824% |
| Disc Medicine, Inc. | -91.02 Million USD | 76.337% |
| Champions Oncology, Inc. | -5.05 Million USD | -326.177% |
| REGENXBIO Inc. | -239.46 Million USD | 91.005% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | -100.957% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 61.369% |
| Cellectar Biosciences, Inc. | -38.76 Million USD | 44.442% |
| Edgewise Therapeutics, Inc. | -112.8 Million USD | 80.906% |
| Vaxart, Inc. | -74.72 Million USD | 71.175% |
| PharmaCyte Biotech, Inc. | - USD | Infinity% |
| Aldeyra Therapeutics, Inc. | -35.2 Million USD | 38.824% |
| Cellectis S.A. | -98.09 Million USD | 78.043% |
| Longeveron Inc. | -20.06 Million USD | -7.373% |
| Repare Therapeutics Inc. | -114.27 Million USD | 81.151% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 95.096% |
| Inozyme Pharma, Inc. | -74.81 Million USD | 71.209% |
| Revolution Medicines, Inc. | -430.58 Million USD | 94.998% |
| Nymox Pharmaceutical Corporation | -6.28 Million USD | -242.487% |
| Third Harmonic Bio, Inc. | -30.78 Million USD | 30.043% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | 71.123% |
| AN2 Therapeutics, Inc. | 4.9 Million USD | 539.302% |
| Anixa Biosciences, Inc. | -10.96 Million USD | -96.434% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 100.468% |
| Denali Therapeutics Inc. | -179.97 Million USD | 88.032% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | -22523.099% |
| Veru Inc. | -89.97 Million USD | 76.061% |
| Corvus Pharmaceuticals, Inc. | -26.87 Million USD | 19.864% |
| Cingulate Inc. | -22.95 Million USD | 6.156% |
| Passage Bio, Inc. | -98.34 Million USD | 78.098% |
| Context Therapeutics Inc. | -25.06 Million USD | 14.052% |
| Exicure, Inc. | -15.53 Million USD | -38.613% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 89.547% |
| Oramed Pharmaceuticals Inc. | -36.97 Million USD | 41.749% |
| Scinai Immunotherapeutics Ltd. | -5.96 Million USD | -261.235% |
| Nuvalent, Inc. | -149.49 Million USD | 85.592% |
| ABVC BioPharma, Inc. | -8.13 Million USD | -164.854% |
| Carisma Therapeutics, Inc. | -85.89 Million USD | 74.924% |
| Unicycive Therapeutics, Inc. | -30.17 Million USD | 28.627% |
| OmniAb, Inc. | -49.73 Million USD | 56.689% |
| Anew Medical, Inc. | -1.3 Million USD | -1555.776% |
| Fennec Pharmaceuticals Inc. | -12.36 Million USD | -74.207% |
| Lipocine Inc. | -16.32 Million USD | -31.958% |
| Lexeo Therapeutics, Inc. Common Stock | -66.67 Million USD | 67.693% |
| Nautilus Biotechnology, Inc. | -74.3 Million USD | 71.012% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | 43.516% |
| G1 Therapeutics, Inc. | -39.01 Million USD | 44.792% |
| Bellerophon Therapeutics, Inc. | -22.18 Million USD | 2.903% |
| Sage Therapeutics, Inc. | -545.07 Million USD | 96.048% |
| Ocugen, Inc. | -64.82 Million USD | 66.775% |
| Mind Medicine (MindMed) Inc. | -92.57 Million USD | 76.732% |
| Q32 Bio Inc. | -86.5 Million USD | 75.1% |
| Brainstorm Cell Therapeutics Inc. | -16.92 Million USD | -27.246% |
| Alumis Inc. Common Stock | -156.89 Million USD | 86.271% |
| Equillium, Inc. | -12.13 Million USD | -77.451% |
| Kyverna Therapeutics, Inc. | -58.47 Million USD | 63.164% |
| Coya Therapeutics, Inc. | -7.9 Million USD | -172.53% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | -14.199% |
| Dominari Holdings Inc. | -22.44 Million USD | 4.015% |
| Edesa Biotech, Inc. | -8.19 Million USD | -162.987% |
| vTv Therapeutics Inc. | -25.41 Million USD | 15.241% |
| Bio-Techne Corporation | 326.66 Million USD | 106.594% |
| Agios Pharmaceuticals, Inc. | -384.86 Million USD | 94.403% |
| Harmony Biosciences Holdings, Inc. | 216.38 Million USD | 109.954% |
| Prelude Therapeutics Incorporated | -131.1 Million USD | 83.572% |
| Candel Therapeutics, Inc. | -37.43 Million USD | 42.457% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 85.745% |
| Nkarta, Inc. | -120.48 Million USD | 82.122% |
| BioCardia, Inc. | -11.56 Million USD | -86.324% |
| Iterum Therapeutics plc | -34.58 Million USD | 37.713% |